JETEMA Co.,Ltd. Logo

JETEMA Co.,Ltd.

Develops and manufactures toxins, fillers, and threads for the aesthetic medicine market.

216080 | KO

Overview

Corporate Details

ISIN(s):
KR7216080002
LEI:
Country:
South Korea
Address:
강원도 원주시 지정면 조엄로 321, 원주시

Description

JETEMA Co., Ltd. is a research-driven biopharmaceutical company specializing in the development and manufacturing of innovative medicines and medical devices for the aesthetic medicine market. The company's core product portfolio includes botulinum toxins, hyaluronic acid-based dermal fillers, and lifting threads. With a strong focus on research and development, JETEMA aims to provide advanced solutions for anti-aging and aesthetic enhancement. The company's name is derived from the Latin word 'Zetéma', meaning 'research', reflecting its commitment to scientific innovation in creating products for a healthy and beautiful life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-06 00:00
전환가액의조정
Korean 12.7 KB
2024-09-06 00:00
주식등의대량보유상황보고서(일반)
Korean 155.4 KB
2024-09-04 00:00
투자판단관련주요경영사항(임상시험결과) (뇌졸중 후 상지근육 경직 치료에서 JTM201의 임상 1상 결과)
Korean 17.5 KB
2024-08-13 00:00
반기보고서 (2024.06)
Korean 1.4 MB
2024-08-12 00:00
주식등의대량보유상황보고서(일반)
Korean 157.8 KB
2024-07-29 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 20.9 KB
2024-07-18 00:00
주식등의대량보유상황보고서(일반)
Korean 153.6 KB
2024-07-05 00:00
주식등의대량보유상황보고서(일반)
Korean 153.6 KB
2024-06-25 00:00
주식등의대량보유상황보고서(일반)
Korean 153.6 KB
2024-06-10 00:00
주식등의대량보유상황보고서(일반)
Korean 153.6 KB
2024-06-04 00:00
투자판단관련주요경영사항(임상시험결과) (제테마더톡신주100단위(JTM201) 중국 임상 1상 결과)
Korean 15.2 KB
2024-05-31 00:00
주식등의대량보유상황보고서(일반)
Korean 153.6 KB
2024-05-14 00:00
분기보고서 (2024.03)
Korean 1.3 MB
2024-05-14 00:00
주식등의대량보유상황보고서(일반)
Korean 153.6 KB
2024-04-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.6 KB

Automate Your Workflow. Get a real-time feed of all JETEMA Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JETEMA Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JETEMA Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.